Eris Lifesciences

₹853.5 6.6 | 0.8%

WEBSITE BSE:540596 NSE : ERIS 10 May, 16:01

Market Cap ₹11612 Cr.

Stock P/E 30.0

P/B 4.6

Current Price ₹853.5

Book Value ₹ 184.7

Face Value 1

52W High ₹971

Dividend Yield 0.86%

52W Low ₹ 605.2

Edit Ratio

Eris Lifesciences Research see more...

Overview Inc. Year: 2007Industry: Pharmaceuticals & Drugs

Eris Lifesciences Ltd is an totally India-based organisation, that is engaged in manufacturing, marketing and selling of generics in the chronic and acute classes of the Indian Pharmaceutical Market. The Company operates inside diverse regions via its seven targeted divisions: Eris, Nikkos, Adura, Montana, Inspira, Victus, Eris Kinedex, Eterna, and Altiza. Its Eris division consists of Atorsave 10, Atorsave 20, Decal, Enoxsave 0.6 and Metaloc XL100 merchandise; its Nikkos division consists of Alerfix, Erinac D, Ezeepam Plus 5, Zenpride OD and Nikotriol merchandise; its Adura division consists of Crevast 5, Glitaris M30, Metafort G1 CP and Olmin 10 products; its Montana department includes Meftaris, Calshine 60K Sachet, Hinder, Rabemon 20 and Vomisave Syrup merchandise; its Inspira department consists of Crevast F 5, Lnbeta 5 and Twichek merchandise, and its Victus department consists of Atorsave D80, Cyblex M 30 XR, Cyblex M 80, Cyblex M 60 XR and Cyblex MV 40.3 products.

Eris Lifesciences Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Eris Lifesciences Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	360	332	306	399	461	423	403	467	505	486
Other Income	7	5	8	3	5	2	1	1	3	4
Total Income	367	337	314	401	466	425	404	468	509	490
Total Expenditure	220	210	209	269	309	286	284	297	324	311
Operating Profit	147	127	105	132	157	139	120	171	185	180
Interest	1	1	1	7	7	3	9	17	16	18
Depreciation	15	17	18	23	29	30	35	41	42	46
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	131	109	85	101	121	107	76	112	126	116
Provision for Tax	12	8	5	8	2	6	14	19	4	14
Profit After Tax	118	101	80	93	119	100	61	94	122	101
Adjustments	0	0	0	2	1	2	4	1	1	1
Profit After Adjustments	118	101	80	95	120	102	65	95	123	103
Adjusted Earnings Per Share	8.7	7.4	5.9	7	8.8	7.5	4.8	7	9.1	7.6

Eris Lifesciences Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	393	509	546	597	749	856	982	1074	1212	1347	1685	1861
Other Income	1	4	3	3	25	26	32	16	9	26	11	9
Total Income	395	513	549	600	775	882	1014	1090	1221	1373	1696	1871
Total Expenditure	307	410	424	425	480	533	637	706	781	862	1148	1216
Operating Profit	87	103	125	175	294	349	377	384	439	511	548	656
Interest	1	0	0	0	1	11	23	2	2	4	26	60
Depreciation	3	5	16	20	23	26	36	50	43	65	117	164
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	83	98	109	154	270	312	317	331	394	442	405	430
Provision for Tax	25	27	20	20	24	17	26	35	39	36	30	51
Profit After Tax	58	71	89	135	247	295	291	297	355	406	374	378
Adjustments	-0	-0	-0	-1	0	-1	-0	-0	0	0	8	7
Profit After Adjustments	58	71	89	134	247	294	291	296	355	406	382	386
Adjusted Earnings Per Share	4.2	5.1	6.5	9.7	17.9	21.4	21.1	21.8	26.2	29.9	28.1	28.5

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	25%	16%	15%	16%
Operating Profit CAGR	7%	13%	9%	20%
PAT CAGR	-8%	8%	5%	20%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	35%	9%	6%	NA%
ROE Average	18%	22%	24%	39%
ROCE Average	17%	23%	24%	45%

Eris Lifesciences Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	106	177	266	300	567	861	1151	1296	1576	1908	2196
Minority's Interest	5	4	4	3	24	25	18	0	0	-0	25
Borrowings	1	0	1	0	0	274	0	0	0	45	644
Other Non-Current Liabilities	17	18	18	20	11	-26	-66	-80	-109	-124	85
Total Current Liabilities	44	71	65	69	129	294	377	220	235	283	521
Total Liabilities	172	270	354	392	732	1428	1481	1437	1703	2113	3471
Fixed Assets	27	75	72	71	232	771	761	875	854	918	2568
Other Non-Current Assets	18	40	119	98	231	290	67	27	313	484	61
Total Current Assets	126	155	163	222	269	367	653	535	536	711	843
Total Assets	172	270	354	392	732	1428	1481	1437	1703	2113	3471

Eris Lifesciences Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	3	2	7	5	9	2	11	8	67	37	51
Cash Flow from Operating Activities	38	90	90	131	200	235	223	271	375	378	292
Cash Flow from Investing Activities	-36	-83	-92	-44	-184	-590	-5	123	-323	-320	-982
Cash Flow from Financing Activities	-3	-2	0	-84	-24	363	-221	-335	-82	-45	688
Net Cash Inflow / Outflow	-1	5	-2	4	-8	8	-3	60	-30	14	-2
Closing Cash & Cash Equivalent	2	7	5	9	2	11	8	67	37	51	56

Eris Lifesciences Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	4.22	5.13	6.47	9.68	17.95	21.39	21.15	21.84	26.16	29.88	28.1
CEPS(Rs)	4.49	5.48	7.59	0	19.59	23.32	23.81	25.54	29.32	34.61	36.12
DPS(Rs)	0	0	0	604.2	0	0	0	2.87	5.5	6.01	7.35
Book NAV/Share(Rs)	7.69	12.82	19.28	21.71	41.25	62.64	83.58	95.26	115.81	140.25	161.28
Core EBITDA Margin(%)	21.86	19.45	21.9	27.93	35.91	37.65	35.13	34.25	34.6	34.77	30.42
EBIT Margin(%)	21.35	19.38	19.74	25.17	36.22	37.74	34.66	31.06	31.85	32	24.42
Pre Tax Margin(%)	21.15	19.32	19.73	25.12	36.08	36.49	32.31	30.85	31.69	31.7	22.92
PAT Margin (%)	14.87	13.94	16.1	21.94	32.9	34.48	29.64	27.61	28.53	29.09	21.2
Cash Profit Margin (%)	15.75	14.87	18.9	25.25	35.94	37.47	33.34	32.29	31.98	33.73	27.83
ROA(%)	42.75	32.09	28.59	36.17	43.89	27.31	20.02	20.33	22.62	21.27	13.4
ROE(%)	75.91	50.12	40.3	47.68	56.9	41.3	28.96	24.28	24.78	23.33	18.25
ROCE(%)	103.88	68.93	49.25	54.56	62.56	35.76	26.54	25.44	27.6	25.29	17.31
Receivable days	14.41	13.97	15.14	14.56	18.07	24.64	27.99	40.93	43.59	39.44	46.91
Inventory Days	30.54	31.57	33.71	31.24	25.19	25.87	27.52	25.85	24.03	27.78	25.78
Payable days	99.28	109.8	135.59	113.55	86.17	166.67	207.67	195.95	155.23	155.58	125.63
PER(x)	0	0	0	0	0	37.15	30.46	16.88	23.11	23.06	20.36
Price/Book(x)	0	0	0	0	0	12.69	7.71	3.87	5.22	4.91	3.55
Dividend Yield(%)	0	0	0	0	0	0	0	0.78	0.91	0.87	1.28
EV/Net Sales(x)	-0.01	-0.01	-0.01	-0.02	0.02	13.2	9.19	4.6	6.74	6.95	5.07
EV/Core EBITDA(x)	-0.02	-0.06	-0.04	-0.05	0.04	32.4	23.96	12.86	18.59	18.31	15.6
Net Sales Growth(%)	43.49	29.45	7.22	9.43	25.54	14.16	14.79	9.36	12.83	11.15	25.1
EBIT Growth(%)	48.06	17.51	10.99	41.38	75.47	18.93	5.43	-1.99	18.83	12.6	-3.46
PAT Growth(%)	57.68	21.34	25.87	51.09	82.86	19.61	-1.3	1.84	19.77	14.26	-7.79
EPS Growth(%)	57.53	21.64	26.05	49.69	85.43	19.17	-1.14	3.27	19.78	14.23	-5.94
Debt/Equity(x)	0.02	0	0	0	0	0.44	0.15	0	0	0.02	0.38
Current Ratio(x)	2.9	2.18	2.5	3.22	2.08	1.25	1.73	2.43	2.27	2.51	1.62
Quick Ratio(x)	2.11	1.73	1.68	2.66	1.75	1.03	1.51	2.12	1.95	2.16	1.41
Interest Cover(x)	109.4	358.55	4974.41	558.56	246.14	30.31	14.76	145.25	200.75	105.81	16.36
Total Debt/Mcap(x)	0	0	0	0	0	0.03	0.02	0	0	0	0.11

Eris Lifesciences Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	52.66	52.66	52.3	52.29	52.7	52.86	52.86	54.91	54.9	54.9
FII	13.34	13.31	15.35	15.39	15.5	14.86	13.78	13.2	13.14	14.27
DII	10.37	10.51	10.66	10.68	9.94	10.02	10.74	14.53	14.56	15.63
Public	23.62	23.52	21.69	21.64	21.85	22.26	22.63	17.37	17.41	15.19
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	7.16	7.16	7.11	7.11	7.17	7.19	7.19	7.47	7.47	7.47
FII	1.81	1.81	2.09	2.09	2.11	2.02	1.87	1.8	1.79	1.94
DII	1.41	1.43	1.45	1.45	1.35	1.36	1.46	1.98	1.98	2.13
Public	3.21	3.2	2.95	2.94	2.97	3.03	3.08	2.36	2.37	2.07
Others	0	0	0	0	0	0	0	0	0	0
Total	13.59	13.59	13.6	13.6	13.6	13.6	13.6	13.6	13.6	13.6

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 155.58 to 125.63days.
Company is almost debt free.

Cons

Stock is trading at 4.6 times its book value.
The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Eris Lifesciences News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Eris Lifesciences

Add Watchlist

Eris Lifesciences Research see more...

Overview Inc. Year: 2007Industry: Pharmaceuticals & Drugs

Eris Lifesciences Share Price

Alert Data

Quarterly Price

Peer Comparison

Eris Lifesciences Quarterly Results

Eris Lifesciences Profit & Loss

Growth Rates

Eris Lifesciences Balance Sheet

Eris Lifesciences Cash Flow

Eris Lifesciences Ratios

Eris Lifesciences Shareholding Pattern

Eris Lifesciences News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!